Songjiang Ma Sells 1,057 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Posted by Mitch Edgeman on Jan 14th, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 1,057 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $10.02, for a total transaction of $10,591.14. Following the sale, the president now directly owns 2,915,194 shares in the company, valued at $29,210,243.88. The trade was a 0.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Songjiang Ma also recently made the following trade(s):

On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $565.60.
On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total value of $9,560.56.
On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.40, for a total value of $24,800.00.
On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total transaction of $25,000.00.
On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00.
On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total transaction of $24,540.00.
On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total value of $21,640.00.
On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total value of $22,100.00.

Gyre Therapeutics Price Performance

Shares of Gyre Therapeutics stock traded up $0.53 during trading hours on Tuesday, reaching $10.52. 105,830 shares of the company’s stock were exchanged, compared to its average volume of 154,951. The business has a fifty day moving average of $11.92 and a two-hundred day moving average of $12.67. Gyre Therapeutics, Inc. has a 1 year low of $8.26 and a 1 year high of $26.37.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its stake in Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after purchasing an additional 90,557 shares during the period. Geode Capital Management LLC raised its position in shares of Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after buying an additional 43,840 shares during the period. Advantage Alpha Capital Partners LP acquired a new position in Gyre Therapeutics in the third quarter valued at approximately $334,000. WINTON GROUP Ltd purchased a new position in Gyre Therapeutics in the second quarter worth approximately $220,000. Finally, Bank of New York Mellon Corp acquired a new stake in Gyre Therapeutics during the second quarter worth $218,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.